Bryan Garnier - Cleantech Energy transition Thyssenkrupp considers listing hydrogen business in Q1 ’22

Report

Bryan Garnier

Xavier Regnard

Cleantech & Energy transition Thyssenkrupp considers listing hydrogen business in Q1 ’22

Cleantech & Energy transition
Thyssenkrupp considers listing hydrogen business in Q1 ’22

Capitalizing on the surging interest for green hydrogen
From chlor-alkali electrolysis to alkaline water electrolysis
A leading player with strong expertise and production capacities
Slightly negative news for other electrolyser pure-players, investors could arbitrate in favour of UCE

17/11/2021 5 EN

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Xavier Regnard

Other Reports from Bryan Garnier

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: FDCA offtake agreement with PLIXXENT

This morning Avantium announced it has signed a five-year conditional offtake agreement with PLIXXENT, an independent polyurethane systems manufacturing house answering various industries, from construction to footwear, energy or automotive. This confirms FDCA as a versatile monomer and extends its

40m 40m 1 EN

Cédric Rossi

Cédric Rossi

BIC: slow improvement amid US macro volatility

Ahead of H1 2025 results due on 30th July, we expect a slow sequential improvement at the top-line level with a flattish LFL sales performance in Q2 (-0.4%e vs. -7% in Q1) thanks to a gradual resumption in wholesale orders in North America. Obviously H1 margins are set to be pressurised by negative

46m 46m 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Initiation of coverage: The 'Clever' way to tackle MDS

Faron Pharmaceuticals is a Finnish biotech developing bexmarilimab (BEX), an immunotherapy in late stage development for the treatment of a rare type of hematologic cancer, high-risk myelodysplastic syndrome (HR-MDS). Encouraging phase 2 data supports a phase 3 trial starting H1 2026, targeting bot

16h / 52m 16h / 52m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Cleantech & Energy transition Thyssenkrupp considers listing hydrogen business in Q1 ’22

Avantium: FDCA offtake agreement with PLIXXENT

BIC: slow improvement amid US macro volatility

Initiation of coverage: The 'Clever' way to tackle MDS

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe